According to UnivDatos, the global Liquid Biopsy Market was valued at USD 8.1 billion in 2024 and is projected to expand at a CAGR of 13.5% over the forecast period (2025–2033). This report provides a comprehensive analysis of the market’s key growth drivers, emerging trends, regional dynamics, and competitive landscape at both global and regional levels.
Access sample report (including graphs, charts, and figures): https://univdatos.com/reports/liquid-biopsy-market?popup=report-enquiry
Market Overview
The liquid biopsy market is experiencing strong growth, primarily fueled by the rising prevalence of cancer, increasing adoption of non-invasive diagnostic methods, and a growing focus on personalized medicine. Further, advances in technology, government-backed healthcare reforms, and substantial investments in R&D are contributing to market expansion.
The demand for faster and simpler cancer detection has accelerated interest in liquid biopsies. The market is also witnessing a sharp increase in strategic collaborations, mergers, and partnerships. Between January and June 2017 alone, 22 inorganic developments were recorded. These collaborations are helping companies gain access to advanced technologies and expand their R&D capabilities, often in partnership with academic and cancer research institutions.
Market Segmentation
By Cancer Type
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
The lung cancer segment led the market in 2020 and is expected to maintain dominance due to its high incidence and demand for early detection.
By Circulating Biomarkers
- Circulating Tumor Cells (CTCs)
- Circulating Tumor DNA (ctDNA)
- Cell-Free DNA (cfDNA)
Among these, circulating tumor cells held the largest market share, supported by their growing use in non-invasive cancer diagnostics and monitoring.
By Product
- Instruments
- Assay Kits
The instruments segment is projected to grow significantly due to rising demand for reliable and specific liquid biopsy assays.
By End User
- Reference Laboratories
- Hospitals & Physician Laboratories
- Academic & Research Centers
Reference laboratories are expected to grow at a high pace, driven by increased outsourcing of tests from hospitals and oncologists to specialized labs.
Geographical Insights
North America
North America, particularly the United States, led the market in 2024. Growth in this region is attributed to a high cancer burden, early adoption of innovative diagnostic tools, and supportive public and private funding.
Asia-Pacific
The Asia-Pacific region is forecasted to grow at the fastest pace. Countries like China, India, and Japan are investing heavily in healthcare infrastructure, increasing awareness, and adopting liquid biopsy technologies—making the region a lucrative market for expansion.
Click here to view the Report Description & TOC https://univdatos.com/reports/liquid-biopsy-market
Leading Market Players
- Roche Diagnostics
- Biocept, Inc.
- Thermo Fisher Scientific Inc.
- Qiagen N.V.
- Bio-Rad Laboratories, Inc.
- Menarini-Silicon Biosystems
- Illumina, Inc.
- MDXhealth SA
- Genomic Health, Inc.
- Guardant Health Inc.
These key players are focusing on product innovation, strategic partnerships, and mergers & acquisitions to strengthen their market presence and drive competitive advantage.
Contact Us:
UnivDatos
Contact Number - +1 978 733 0253
Email - contact@univdatos.com
Website - www.univdatos.com
Linkedin- https://www.linkedin.com/company/univ-datos-market-insight/mycompany/
